Neovasc Inc. (TSE:NVC), a medical tech stock, popped after announcing an investment from Boston Scientific Corporation
Sean Mason | December 2, 2016 | SmallCapPower
A big investment by Boston Scientific boosted a medical tech stock Friday. Here’s some small stocks making big moves on Friday, December 2, 2016 (as of 4 pm EST):
Medical tech stock Neovasc Inc. (TSE:NVC) powered 66% higher to $1.16 on Friday after announcing that Boston Scientific Corporation has agreed to acquire Neovasc’s tissue processing technology and facility for approximately US$67,909,800, and has committed to invest an additional US$7,090,200 in Neovasc for a 15% equity interest in the Company.
As well, shares of American Lithium Corp. (CVE:LI) slid 30% to $0.21 as the lithium explorer said its QA/QC process has found material flaws in the sample assay results announced August 11, 2016; October 12, 2016; October 21, 2016, and November 3, 2016.
YDreams Global Interactive Technologies Inc. (CVE:YD), meanwhile, reported that it will use its knowledge of Virtual Reality, gaming and immersive experiences to develop training solutions for military use. YDreams Global stock popped 45% to $0.225 following the announcement.
Finally, Gold Reserve Inc. (CVE:GRZ) shares climbed 15% to $5.21 after the gold project developer announced that it has agreed to further modify the settlement agreement previously entered into with Venezuela, in which the first payment of US$300 million, originally scheduled for November 30, 2016, is now rescheduled to take place on or before December 15, 2016.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
